Delivery Order SPE2DB20D3103-SPE2DB21FM0P0
- Not listed
- This federal contract award, valued at $17,067.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,069.60, is a delivery order under the DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, worth up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award, valued at $28,753.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the agency's Indefinite Delivery Contract (IDC) with the company, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products and...
- This federal contract award, valued at $2,407.04, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and...
- This federal contract award, valued at $32,443.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies,...
- This federal contract award, valued at $3,461.66, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. The IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications,...
- This federal contract award, valued at $1,222.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of...
- This federal contract award, valued at $11,636.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, which has a ceiling value of $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical...
- This federal contract award, valued at $3,434.68, was issued to the prime contractor Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for pharmaceutical and medical supply products. The contract is a delivery order under an Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
- This federal contract award, valued at $3,009.06, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under DLA's larger Indefinite Delivery Contract (IDC) with AmerisourceBergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FM0P0Delivery Order
This federal contract award, valued at $3,388.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract award does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 1/7/21 |